Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daxdilimab in Active Proliferative Lupus Nephritis
NCT05540665Phase 2Terminated
- Sponsor
- Amgen
- Start
- Apr 2023
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of daxdilimab in lupus nephritis (LN), sponsored by Amgen. Started Apr 2023; status: terminated.
02
Drugs
daxdilimab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT05540665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05540665.